Genentech Holly Springs Manufacturing Facility

Genentech broke ground in Holly Springs in August 2025 on a $700 million plant. Five months later the number changed. On January 20, 2026 the company more than doubled the investment to roughly $2 billion, one of the largest single-year capital increases the Research Triangle has seen from a pharmaceutical manufacturer.

Project Scope

The campus covers about 700,000 square feet dedicated to fill-finish operations and device assembly, supporting Genentech’s metabolic portfolio including next-generation obesity therapies. It is the company’s first manufacturing site on the East Coast. Target for operations is 2029.

Flad Architects leads design with Jacobs providing engineering, and Gilbane Building Company is running the work as construction manager. North Carolina-based SouthernCross Construction is part of the site team. The job commitment to Wake County rose alongside the capital increase, above the original 420-position pledge in the incentive filings.

Why It Matters

Fill-finish is where pharmaceutical capital has been going since the GLP-1 boom outran existing capacity. Drug substance is the harder chemistry, but finished dose is where the bottleneck actually sits, and a 700,000-square-foot facility dedicated to it is a bet that obesity therapy volumes hold through the 2030s.

Holly Springs is now a genuine cluster. Fujifilm Diosynth and Amgen both build there, which means three owners are competing for the same clean-room subcontractors, the same process piping crews, and the same commissioning and qualification talent inside a 10-mile radius. Contractors who can staff a validated cleanroom fit-out in the Triangle have pricing power right now, and a doubled budget on one of the three sites does not make that easier for the other two.

Project Team & Details